Insider Trading April 15, 2026 05:33 PM

Conagra Director Adds $250,402 in Shares as Stock Trades Near 52-Week Low

Insider purchase, high yield and an impending CEO transition put spotlight on packaged-foods maker's valuation

By Leila Farooq CAG
Conagra Director Adds $250,402 in Shares as Stock Trades Near 52-Week Low
CAG

Conagra Brands director John J. Mulligan purchased 17,500 shares on April 14, 2026, investing $250,402 at $14.3087 per share. The transaction occurred while the stock sits close to its 52-week low and amid an announced CEO succession. Analysts have responded with fresh coverage and target updates, underscoring questions about valuation as the company yields a sizable dividend.

Key Points

  • Director John J. Mulligan bought 17,500 Conagra shares on April 14, 2026, spending $250,402 at $14.3087 per share; he now directly owns 20,728 shares.
  • Conagra's stock is trading near its 52-week low and InvestingPro assigns a Fair Value of $19, flagging the shares as among the platform's most undervalued.
  • Leadership will change on June 1, 2026, when John Brase becomes President and CEO; several analysts updated coverage and price targets following the announcement.

Director John J. Mulligan acquired 17,500 shares of Conagra Brands Inc. common stock on April 14, 2026, paying $14.3087 per share for a total outlay of $250,402. Following the filing that reported the trade, Mulligan directly holds 20,728 Conagra shares.

The trade came as Conagra's stock was trading near its 52-week low - the low point listed at $14.22 - while the most recent quote sat at $14.09. Market valuation commentary from InvestingPro cited a Fair Value estimate of $19 for the shares, ranking Conagra among the platform's most undervalued names.

Investors will note the company's pronounced income characteristic: Conagra offers a 9.8% dividend yield and, according to filings, has paid dividends for 51 consecutive years.


In parallel with the insider purchase, the company disclosed a leadership transition that may shape investor expectations. John Brase is slated to take the helm as President and CEO effective June 1, 2026. Brase joins the top role from his prior position as COO at SJM and after holding senior posts at PG. He will replace Sean Connolly, who is stepping down after more than a decade with the company.

That succession news prompted several sell-side reactions. BTIG initiated coverage with a Neutral rating, noting valuation concerns as the stock is trading at roughly nine times its fiscal 2027 earnings per share. BofA Securities maintained an Underperform rating and left a $15 price target in place. Stifel kept a Hold rating and assigned a $17 target price. These analyst moves accompanied the leadership announcement and have attracted investor attention as market participants reassess Conagra's outlook.

The combination of an insider purchase, a high dividend yield and a near-term CEO change creates a focal point for shareholders. Mulligan's purchase provides a discrete data point on insider sentiment, while the analyst updates reflect differing views on valuation and near-term earnings multiples.

Market participants will likely watch trading levels, dividend dynamics and the incoming CEO's early strategic signals as the June transition approaches.

Risks

  • Valuation uncertainty - analysts cited concerns with the stock trading near nine times fiscal 2027 EPS, which may constrain near-term upside for equity investors.
  • Leadership transition - a new CEO taking effect June 1, 2026 creates execution risk as the company adapts to new management.
  • Market-level downside - shares are trading close to their 52-week low, a factor that could weigh on investor sentiment and sector flows into packaged foods.

More from Insider Trading

Photronics Director Sells $225,000 in Stock After Exercising Options; Company Posts Quarterly Beat and Advances Mask Capability Apr 15, 2026 Genprex Director Disposes of Small Holding as Company Advances Gene Therapy IP and Data Presentations Apr 15, 2026 Arista CEO Jayshree Ullal Sells $16.9M in ANET Stock Under 10b5-1 Plan Apr 15, 2026 Oruka Therapeutics CMO Disposes $462,829 in Stock as Analysts Lift Targets on ORKA-001 Progress Apr 15, 2026 GameStop General Counsel Disposes of $90.7K in GME Shares Under 10b5-1 Plan Apr 15, 2026